Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 2Phase NA 1

Status

Completed 4Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 7INDUSTRY 3

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 7

Conditions

Breast Neoplasms 1889Carcinoma, Non-Small-Cell Lung 1350Prostatic Neoplasms 980Colorectal Neoplasms 851Multiple Myeloma 741Leukemia, Myeloid, Acute 725Neoplasms 691Lung Neoplasms 680Neoplasm Metastasis 642Lymphoma 579Carcinoma, Hepatocellular 571Pancreatic Neoplasms 567Stomach Neoplasms 523Leukemia 511Recurrence 493Leukemia, Lymphocytic, Chronic, B-Cell 459Precursor Cell Lymphoblastic Leukemia-Lymphoma 452Melanoma 451Lymphoma, Non-Hodgkin 443Ovarian Neoplasms 426Lymphoma, Large B-Cell, Diffuse 423Squamous Cell Carcinoma of Head and Neck 416Myelodysplastic Syndromes 416Head and Neck Neoplasms 404Brain Neoplasms 403Rectal Neoplasms 397Glioblastoma 375Carcinoma, Renal Cell 350Hodgkin Disease 338Esophageal Neoplasms 337

Interventions

Docetaxel 2sargramostim 1epothilone B 1cabazitaxel 1Sunitinib 1Prednisone 1Everolimus 1Carboplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Hormone Refractory Prostate Cancer × Clear all
NCT02955082 2026-02-04

BARCODE2

Institute of Cancer Research, United Kingdom

Phase 2 Active not recruiting
305 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT01741116 2021-02-18

Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer

Korean Cancer Study Group

Phase 2 Completed
44 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT01518283 2017-07-02

Study of Weekly Cabazitaxel for Advanced Prostate Cancer

Spanish Oncology Genito-Urinary Group

Phase 2 Completed
74 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT00629525 2015-03-03

RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer

Duke University

Phase 2 Completed
35 enrolled 6 charts
Genitourinary

Hormone Refractory Prostate Cancer

NCT00313482 2012-05-11

PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

Veeda Oncology

Phase 2 Terminated
35 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT00407251 2010-11-05

Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy

British Columbia Cancer Agency

Phase 2 Completed
73 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT00795171 2010-08-18

Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer

Medical University of Vienna

Phase 2 Unknown
60 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡